Table 1.
Comparison of publications, citations and percentage of clinical trials in cancer for polymer, liposome and monoclonal antibody therapeutics.‡
| Cancera | Platinatesa | Camptothecinsb | ||
|---|---|---|---|---|
| All | Publications | 2,850,000 | 19,000 | 10,000 |
| Clinical Trials | 86,000 (3%) | 2100 (11%) | 1500 (15%) | |
| Polymers | Publications | 9000 | 500 | 400 |
| Clinical Trials | 95(1%) | 4 (1%) | 5 (1%) | |
| Citations per Publicationa | 11.67 | 13.84 | 11.70b | |
| Liposomes | Publications | 12,000 | 600 | 300 |
| Clinical Trials | 500 (4%) | 90 (15%) | 14 (5%) | |
| Citations per Publicationa | 9.83 | 8.80 | 5.79b | |
| Monoclonal Antibodies | Publications | 35,000 | - | - |
| Clinical Trials | 2,800 (8%) | - | - | |
| Citations per Publicationa | 7.36 | - | - |
Citations per publication reported between the years 1985 and 2005.
Camptothecin citations per publication reported between the years 1995 and 2005.
Search terms - All Cancer: cancer NOT reviews; All Cancer Platinates: cancer AND platinum therapy NOT reviews; All Cancer Camptothecins: cancer AND camptothecin NOT review: Cancer Polymers: cancer AND polymer NOT review; Cancer Polymer Platinates: cancer AND polymer AND platinum therapy NOT review; Cancer Polymer Camptothecins: cancer AND polymer AND camptothecin NOT review; Cancer Liposomes: cancer AND liposome NOT review; Cancer Liposomal Platinates: cancer AND liposome AND platinum therapy; Cancer Liposomal Camptothecins: cancer AND liposome AND camptothecin; Cancer Monoclonal Antibodies: cancer AND monoclonal antibody therapy NOT review; Clinical Trials: Identified using the above search strings and the clinical trial selection in SciFinder Scholar.